Last reviewed · How we verify
Oxymorphone ER
At a glance
| Generic name | Oxymorphone ER |
|---|---|
| Also known as | Opana ER, OPANA® ER (oxymorphone HCl) Extended-Release Tablets, Opana, Opana ER, Opana |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning (PHASE4)
- Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)
- Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children (PHASE3)
- Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects (PHASE3)
- Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain (PHASE4)
- Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin) (PHASE4)
- Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions (PHASE1)
- Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxymorphone ER CI brief — competitive landscape report
- Oxymorphone ER updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI